AHA 2019 ICYMI: Summaries of 11 late-breaking clinical trials presented at the 2019 Scientific Sessions held in Philadelphia, PA, Nov 16-18.
Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD
Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Bempedoic Acid Associated with Reduced CV Risk in Statin-Intolerant Individuals Regardless of Ethnicity
ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes for up to 1 Year, According to New Data
New research highlights another benefit of COVID-19 vaccination, reported researchers.
Aspirin Use among Older Adults: Daily Dose
Your daily dose of the clinical news you may have missed.